IP Library Granted Patent US 10,471,022
Granted Patent B2
US 10,471,022 · App. 16/249,732 · Granted Nov 12, 2019

Treatment of fragile X syndrome with cannabidiol

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,471,022
App. No.
16/249,732
Granted
Nov 12, 2019
Kind
B2
Abstract

The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.

Claims (7)

1. A method of treating a human suffering from Fragile X Syndrome comprising:

transdermally administering via a gel or cream, 250 mg or 500 mg of cannabidiol total daily to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.

2. The method of claim 1 , wherein the cannabidiol is (-)-cannabidiol.

3. The method of claim 1 , wherein the cannabidiol is formulated as a gel.

4. The method of claim 3 , wherein the cannabidiol is formulated as a permeation-enhanced gel.

5. The method of claim 1 , wherein the cannabidiol is administered in two daily doses.

6. The method of claim 1 , wherein the cannabidiol is transdermally administered on the human's upper arm and shoulder.

Assignments (2)
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 18, 2026
From: HARMONY BIOSCIENCES MANAGEMENT, INC. (F/K/A ZYNERBA PHARMACEUTICALS, INC.)
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075642/0639 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2019
From: SEBREE, TERRI; BONN-MILLER, MARCEL; GUTTERMAN, DONNA; TICH, NANCY; MESSENHEIMER, JOHN
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 048318/0477 →